|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online March 7, 2007
doi: 10.1242/10.1242/jcs.03409
Commentary |
Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA
* Author for correspondence (e-mail: joann_trejo{at}med.unc.edu)
Accepted 15 January 2007
Protease-activated receptors (PARs) are G-protein-coupled receptors (GPCRs) that are activated by a unique proteolytic mechanism. PARs play crucial roles in hemostasis and thrombosis, as well as in inflammation and vascular development. Coagulant proteases, which are generated at sites of vascular injury, act mainly through PARs to elicit signalling in a variety of cell types. Since PARs are irreversibly activated signalling must be tightly regulated. Desensitization and trafficking of proteolytically activated PARs control the magnitude, duration and spatial aspects of receptor signalling. Recent studies have revealed novel endocytic sorting mechanisms that regulate PAR signalling. PARs have also been implicated in tumor progression. PARs are overexpressed in several types of malignant cancer, transmit signals in response to tumor-generated proteases and promote tumor growth, invasion and metastasis. Recent work also indicates that matrix metalloprotease 1 (MMP-1) signals through PAR1 to promote tumor growth and invasion. In addition to PAR overexpression, tumor cells display aberrant PAR1 trafficking, which causes persistent signalling and cellular invasion. Thus, a novel type of gain-of-function in GPCR signalling in cancer can be acquired through dysregulation of receptor trafficking.
Key words: Arrestin, GPCR, Thrombin, Trafficking, Coagulant protease
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Ayoub, M. Damian, C. Gespach, E. Ferrandis, O. Lavergne, O. De Wever, J.-L. Baneres, J.-P. Pin, and G. P. Prevost Inhibition of Heterotrimeric G Protein Signaling by a Small Molecule Acting on G{alpha} Subunit J. Biol. Chem., October 16, 2009; 284(42): 29136 - 29145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Vermeer, J. Denker, M. Estin, T. O. Moninger, S. Keshavjee, P. Karp, J. N. Kline, and J. Zabner MMP9 modulates tight junction integrity and cell viability in human airway epithelia Am J Physiol Lung Cell Mol Physiol, May 1, 2009; 296(5): L751 - L762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Russo, U. J. K. Soh, and J. Trejo Proteases Display Biased Agonism at Protease-Activated Receptors: Location matters! Mol. Interv., April 1, 2009; 9(2): 87 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Elzer, D. A. Heitzman, M. I. Chernin, and J. F. Novak Differential Effects of Serine Proteases on the Migration of Normal and Tumor Cells: Implications for Tumor Microenvironment Integr Cancer Ther, December 1, 2008; 7(4): 282 - 294. [Abstract] [PDF]
|
|
|
|
 |
|
 J. S. Blackburn and C. E. Brinckerhoff Matrix Metalloproteinase-1 and Thrombin Differentially Activate Gene Expression in Endothelial Cells via PAR-1 and Promote Angiogenesis Am. J. Pathol., December 1, 2008; 173(6): 1736 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Walsh, J. Radeff-Huang, R. Matteo, A. Hsiao, S. Subramaniam, D. Stupack, and J. H. Brown Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61 FASEB J, November 1, 2008; 22(11): 4011 - 4021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rallabhandi, Q. M. Nhu, V. Y. Toshchakov, W. Piao, A. E. Medvedev, M. D. Hollenberg, A. Fasano, and S. N. Vogel Analysis of Proteinase-activated Receptor 2 and TLR4 Signal Transduction: A NOVEL PARADIGM FOR RECEPTOR COOPERATIVITY J. Biol. Chem., September 5, 2008; 283(36): 24314 - 24325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Agarwal, L. Covic, L. M. Sevigny, N. C. Kaneider, K. Lazarides, G. Azabdaftari, S. Sharifi, and A. Kuliopulos Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer Mol. Cancer Ther., September 1, 2008; 7(9): 2746 - 2757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Ramsay, Y. Dong, M. L. Hunt, M. Linn, H. Samaratunga, J. A. Clements, and J. D. Hooper Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors (PARs): KLK4 AND PAR-2 ARE CO-EXPRESSED DURING PROSTATE CANCER PROGRESSION J. Biol. Chem., May 2, 2008; 283(18): 12293 - 12304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Salah, M. Maoz, G. Pizov, and R. Bar-Shavit Transcriptional Regulation of Human Protease-Activated Receptor 1: A Role for the Early Growth Response-1 Protein in Prostate Cancer Cancer Res., October 15, 2007; 67(20): 9835 - 9843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Wolfe, A. Marchese, and J. Trejo Ubiquitination differentially regulates clathrin-dependent internalization of protease-activated receptor-1 J. Cell Biol., June 21, 2007; 177(5): 905 - 916. [Abstract] [Full Text] [PDF]
|
|
